Hepatitis B Breakthrough
GSK Secures Japan's First Functional Cure Approval for Chronic Hepatitis B
Key Points
Functional cure definition: a functional cure is achieved when HBV DNA and HBsAg are undetectable for at least 24 weeks after stopping bepirovirsen therapy.
In the subgroup with baseline HBsAg ≤1,000 IU/mL (about 45% of CHB patients), the functional cure rate reached 26% in the B-Well trials.
Achieving HBsAg loss is linked to substantial long-term risk reductions, including an 89% drop in liver cancer risk and a 62% reduction in all-cause mortality.
Most common adverse events with bepirovirsen in the trials include injection-site erythema, local pain, and transient elevations in liver enzymes.
The CHB burden in Japan is substantial, with nearly one million people affected and around 4,000 deaths annually, underscoring the public health impact of the new therapy.
GlaxoSmithKline's Hibsago (bepirovirsen) has won Japan's approval as the world's first functional cure for chronic hepatitis B, a major breakthrough for the roughly one million Japanese patients living with the disease Reuters. The drug showed a 19% functional cure rate in trials—meaning patients could stop taking daily medications for life—compared to just 1% with standard care TipRanks.
Japan approved Hibsago under an accelerated pathway for high-need therapies, based on phase III data showing that patients with lower baseline viral markers achieved a 26% cure rate GSK/MarketScreener. The approval could reshape how doctors treat hepatitis B worldwide and reduce liver cancer deaths by up to 89% for patients who achieve functional cure TipRanks.
What a Functional Cure Actually Means
A functional cure is when HBV DNA and HBsAg—two key viral markers—become undetectable and stay undetectable for at least 24 weeks after stopping Hibsago MarketScreener. This is different from a traditional cure because the virus may not be completely gone. But patients no longer need lifelong daily medication Reuters.
The B-Well trials showed the strongest results in a specific patient group: those with baseline HBsAg levels of 1,000 IU/mL or lower (about 45% of all hepatitis B patients). In that subgroup, 26% achieved functional cure MarketScreener.
Why This Approval Matters for Public Health
Japan has nearly one million people with chronic hepatitis B and about 4,000 deaths per year from the disease Reuters. Hibsago's approval offers an escape route from lifelong daily therapy for eligible patients, potentially preventing thousands of deaths and cases of liver cancer TipRanks.
Patients who achieve HBsAg loss see major health gains: an 89% drop in liver cancer risk and a 62% reduction in all-cause mortality TipRanks. These numbers underscore why the new drug could transform treatment for one of the world's most stubborn viral infections Reuters.
Side Effects and Who Can Get Hibsago
In trials, the most common side effects were injection-site redness, local pain, and temporary liver enzyme spikes TipRanks. Most patients tolerated the drug well enough to complete treatment Reuters.
Hibsago is approved for adults who have taken nucleos(t)ide analogues—standard hepatitis B drugs—for at least six months and meet specific viral markers MarketScreener. This means it's not a first-line therapy but a step forward for patients already on existing treatments TipRanks.
What Comes Next for GSK and Global Regulators
Japan's approval is the first global sign-off for Hibsago, but GSK is pursuing regulatory decisions in other major markets Reuters. The Japanese milestone could accelerate approval elsewhere and reshape how hepatitis B is managed worldwide TipRanks.
Separately, GSK won FDA priority review for its cancer drug Jemperli ADVFN, showing the company is advancing multiple pipelines at once. The hepatology wins signal a shift in how doctors think about chronic hepatitis B—from lifelong management to potential cure Reuters.
Sentiment
Mostly PositivePublishers
10
Articles
35
Reach
45
